

VEGF121

Catalog # PVGS1331

Product Information

Primary Accession P15692-9
Species Human

Sequence Pro28-Arg147, expressed with an N-terminal Met

Purity > 95% as analyzed by SDS-PAGE

> 95% as analyzed by HPLC

Endotoxin Level

Expression System E. coli

Formulation Lyophilized after extensive dialysis against PBS.

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

ddH₂O or PBS up to 100 □g/ml.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than

-70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw

cycles.

Additional Information

Target Background VEGF-A121 is one of five isoforms (121, 145, 165, 189, and 206) of VEGF

protein, a cytokine belonging to the Platelet Differentiation Growth Factor (PDGF) family, and existing as a disulfide-linked homodimeric glycoprotein. In contrast to the longer isoforms, VEGF-A121 is more freely diffusible, and cannot bind to heparin. In vivo, VEGF is expressed predominantly in lung, heart, kidney, and adrenal glands, and the expression of VEGF is up-regulated by a number of growth factors, including PDGF, Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), and Tumor Necrosis Factor (TNF). VEGF signals via binding to two tyrosine kinase receptors: the Fms-like tyrosine kinase 1 (Flt-1) and the kinase domain receptor (KDR). VEGF is a specific mitogen and survival factor, contributing to abnormal angiogenesis and

cancer development.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.